Teladoc Health, Inc. · NYSE:TDOC
Teladoc Health — Q1 2025 Earnings Presentation
13 slides from Teladoc Health's earnings presentation, Apr 30, 2025
Slide 1: 1Q-25 Quarterly Results
1Q-25 Quarterly Results Teladoc HEALTH
Slide 2: Cautionary Note
Cautionary Note • This presentation contains, and the officers of Teladoc Health, Inc. (the “Company” or “Teladoc Health”) may make, “forward-looking” statements that are based on management’s beliefs and assumptions and on information currently available to management. These forward-looking stateme
Slide 3: Financial Highlights
Financial Highlights 1Q-25 Adj. 1Q-25 Revenue of 1Q-25 Net loss per EBITDA(2) of $629M, (3)% y/y share of $(0.53)(1) $58.1M, (8)% y/y FY-25 Revenue outlook range FY-25 Net loss per share FY-25 Adj. EBITDA outlook of $2,468M to $2,576M outlook range of range of $263M to $304M $(1.40) to $(0.90) • 2Q-
Slide 4: 1Q-25 Consolidated Revenue & Adj. EBITDA
1Q-25 Consolidated Revenue & Adj. EBITDA Revenue ($ millions) Adj. EBITDA ($ millions)(1) 70 700 $646 $63.1 $629 60 $58.1 600 500 50 400 40 300 30 200 20 100 10 0 0 1Q-24 1Q-25 1Q-24 1Q-25 (1) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentation. 4
Slide 5: Quarterly Segment Results
(1) Quarterly Segment Results Integrated Care Segment Revenue ($ millions) BetterHelp Segment Revenue ($ millions) 600 300 $269 $265 $257 $250 $240 $377 $377 $384 $391 $389 400 200 200 100 0 0 1Q-24 2Q-24 3Q-24 4Q-24 1Q-25 1Q-24 2Q-24 3Q-24 4Q-24 1Q-25 Integrated Care Segment Adjusted EBITDA ($ mill
Slide 6: 1Q-25 Revenue: U.S. & International
1Q-25 Revenue: U.S. & International U.S. Revenue ($ millions) International Revenue ($ millions) 600 125 $548 $525 $104 500 $99 100 400 75 300 50 200 25 100 0 0 1Q-24 1Q-25 1Q-24 1Q-25 6
Slide 7: Quarterly Key Operating Metrics
Quarterly Key Operating Metrics U.S. Integrated Care Members(1) (millions) BetterHelp Paying Users(2) (thousands) 150m 600k 102.5 415 407 398 400 397 100m 91.8 92.4 93.9 93.8 400k 50m 200k 0m 0k 1Q-24 2Q-24 3Q-24 4Q-24 1Q-25 1Q-24 2Q-24 3Q-24 4Q-24 1Q-25 Average Revenue per Month per U.S. Chronic Ca
Slide 8: Quarterly Adjusted EBITDA & Adjusted EBITDA Margin
Quarterly Adjusted EBITDA & Adjusted EBITDA Margin Adj. EBITDA(1) & Adj. EBITDA Margin ($ millions) 100m 16% 13.9% 13.0% 14% 11.7% 75m 12% 9.8% 9.2% 10% 50m 8% $89.5 $83.3 $74.8 6% $63.1 $58.1 25m 4% 2% 0m 0% 1Q-24 2Q-24 3Q-24 4Q-24 1Q-25 Adj. EBITDA Adj. EBITDA Margin (1) See reconciliation of GAAP
Slide 9: Balance Sheet and Cash Flow Highlights
Balance Sheet and Cash Flow Highlights • Cash and Cash Equivalents (as of of March 31, 2025): $1.19B • Convertible Senior Notes (1) (as of March 31, 2025): $1.54B • Operating Cash Flow (1Q-25): $16M • Free Cash Flow (2) (1Q-25): $(16)M (1) Includes $0.55B of current convertible senior notes that mat
Slide 10: Outlook: 2Q-25 and FY-25
Outlook: 2Q-25 and FY-25 2Q-25 Y/Y % Growth FY-25 Y/Y % Growth Revenue ($M) $614 to $633 (4)% to (1)% $2,468 to $2,576 (4)% to 0% Net loss per share $(0.40) to $(0.20) NM $(1.40) to $(0.90) NM Adj. EBITDA ($M) $56 to $70 (37)% to (22)% $263 to $304 (15)% to (2)% US Integrated Care 101.5 to 102.5 10%
Slide 11: Appendix
Teladc c. HEALTH © Appendix
Slide 12: Reconciliation of Net Loss to Adjusted EBITDA
Reconciliation of Net Loss to Adjusted EBITDA 1Q-24 2Q-24 3Q-24 4Q-24 1Q-25 Net loss $(81,889) $(837,671) $(33,276) $(48,409) $(93,012) Add: Provision for income taxes 2,690 3,884 780 238 (18,255) Other expense (income), net 370 563 (2,239) 7,341 (2,435) Interest expense 5,649 5,648 5,660 6,846 5,76
Slide 13: Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow
Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow 1Q-25 Net cash provided by operating activities $15,919 Capital expenditures (2,726) Capitalized software development costs (28,859) Capex (31,585) Free Cash Flow $(15,666) (in 000s) 13